

NCT02596555 comparison:

Summary:
CHIA has 22 criteria while your personal folder has 22 criteria
Total found criteria: 22/22
Total not Found: 0/22
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Age =18 years                                      │ Age ≥18 years                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Objectively confirmed diagnosis of acute PE by     │ Objectively confirmed diagnosis of acute PE by     │
│ multidetector CT angiography,                      │ multidetector CT angiography,                      │
│ ventilation/perfusion lung scan, or selective      │ ventilation/perfusion lung scan, or selective      │
│ invasive pulmonary angiography, according to       │ invasive pulmonary angiography, according to       │
│ established diagnostic criteria, with or without   │ established diagnostic criteria, with or without   │
│ symptomatic deep vein thrombosis                   │ symptomatic deep vein thrombosis                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absence of hemodynamic collapse, or                │ Absence of hemodynamic collapse, or                │
│ decompensation, at presentation; Hemodynamic       │ decompensation, at presentation; Hemodynamic       │
│ collapse or decompensation                         │ collapse or decompensation                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ At least one sign of RV pressure                   │ At least one sign of RV pressure                   │
│ overload/dysfunction on CT angiography or          │ overload/dysfunction on CT angiography or          │
│ echocardiography                                   │ echocardiography                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signs of myocardial injury as indicated by         │ Signs of myocardial injury as indicated by         │
│ elevated troponin levels                           │ elevated troponin levels                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signs of (RV) failure as indicated by NT-proBNP    │ Signs of (RV) failure as indicated by NT-proBNP    │
│ levels >600 pg/ml at baseline                      │ levels \>600 pg/ml at baseline                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability of the subject to understand the character │ Ability of the subject to understand the character │
│ and individual consequences of the clinical trial; │ and individual consequences of the clinical trial; │
│ signed and dated informed consent of the subject   │ signed and dated informed consent of the subject   │
│ available before the start of any specific trial   │ available before the start of any specific trial   │
│ procedures                                         │ procedures                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy (a negative serum or urine pregnancy     │ Pregnancy (a negative serum or urine pregnancy     │
│ test should be available for women of child-       │ test should be available for women of child-       │
│ bearing potential before study inclusion) or       │ bearing potential before study inclusion) or       │
│ lactation                                          │ lactation                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential who do not         │ Women of childbearing potential who do not         │
│ practice a medically accepted highly effective     │ practice a medically accepted highly effective     │
│ contraception during the trial and one month       │ contraception during the trial and one month       │
│ beyond                                             │ beyond                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypersensitivity to the investigational │ History of hypersensitivity to the investigational │
│ medicinal product or to any drug with similar      │ medicinal product or to any drug with similar      │
│ chemical structure or to any excipient present in  │ chemical structure or to any excipient present in  │
│ the pharmaceutical form of the investigational     │ the pharmaceutical form of the investigational     │
│ medicinal product                                  │ medicinal product                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in another clinical trial during the │ Participation in another clinical trial during the │
│ present clinical trial or within the last three    │ present clinical trial or within the last three    │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medical or psychological condition that would not  │ Medical or psychological condition that would not  │
│ permit completion of the trial or signing of       │ permit completion of the trial or signing of       │
│ informed consent                                   │ informed consent                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of a fibrinolytic agent, surgical              │ Use of a fibrinolytic agent, surgical              │
│ thrombectomy, interventional (catheter-directed)   │ thrombectomy, interventional (catheter-directed)   │
│ thrombus aspiration or lysis, or use of a cava     │ thrombus aspiration or lysis, or use of a cava     │
│ filter to treat the index episode of PE            │ filter to treat the index episode of PE            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with any therapeutically dosed           │ Treatment with any therapeutically dosed           │
│ anticoagulant for more than 48 hours prior to      │ anticoagulant for more than 48 hours prior to      │
│ enrolment                                          │ enrolment                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Need for long-term treatment with a low molecular  │ Need for long-term treatment with a low molecular  │
│ weight heparin, vitamin K antagonists or NOAC, for │ weight heparin, vitamin K antagonists or NOAC, for │
│ an indication other than the index PE episode, or  │ an indication other than the index PE episode, or  │
│ for antiplatelet agents except acetylsalicylic     │ for antiplatelet agents except acetylsalicylic     │
│ acid at a dosage =100 mg/day                       │ acid at a dosage ≤100 mg/day                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active bleeding or known significant bleeding risk │ Active bleeding or known significant bleeding risk │
│ (e.g., gastrointestinal ulcer, malignant           │ (e.g., gastrointestinal ulcer, malignant           │
│ neoplasms, injuries or recent surgeries of the     │ neoplasms, injuries or recent surgeries of the     │
│ brain, spinal cord or eyes, recent intracranial    │ brain, spinal cord or eyes, recent intracranial    │
│ bleedings, known or suspected esophagus varices,   │ bleedings, known or suspected esophagus varices,   │
│ aneurysms or intraspinal or intracranial vascular  │ aneurysms or intraspinal or intracranial vascular  │
│ abnormalities)                                     │ abnormalities)                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Artificial heart valves requiring treatment with   │ Artificial heart valves requiring treatment with   │
│ an anticoagulant                                   │ an anticoagulant                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal insufficiency with estimated creatinine      │ Renal insufficiency with estimated creatinine      │
│ clearance <30 ml/min/1.73m2                        │ clearance \<30 ml/min/1.73m2                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic liver disease with aminotransferase levels │ Chronic liver disease with aminotransferase levels │
│ two times or more above the local upper limit of   │ two times or more above the local upper limit of   │
│ normal range                                       │ normal range                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant administration of strong inhibitors of │ Concomitant administration of strong inhibitors of │
│ P-glycoprotein like ketoconazole, cyclosporin,     │ P-glycoprotein like ketoconazole, cyclosporin,     │
│ itraconazole or dronedarone                        │ itraconazole or dronedarone                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unwillingness or inability to adhere to treatment  │ Unwillingness or inability to adhere to treatment  │
│ or to the follow-up visits                         │ or to the follow-up visits                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy less than 6 months                 │ Life expectancy less than 6 months                 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                            │
╞════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Intermediate-risk category of PE severity indicated by a positive (score ≥1) simplified pulmonary  │
│ embolism severity index (sPESI), in combination with the presence of at least one of the following │
│ criteria at presentation                                                                           │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                  │
╘════════════════════════════════════════════════════════════════════════════════════════════════════╛